Policy & Regulation
Neurana Pharmaceuticals completes 1,000 patient enrolments for Phase three RESUME-1 Study of tolperisone
30 November 2021 -

Neurana Pharmaceuticals Inc., a US-based, privately held, clinical-stage, biotechnology company, announced on Monday that it has completed the enrolment of 1,000 patients for the Phase three RESUME-1 Study of tolperisone intended for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.

The company expects to report topline data in the first quarter of 2022.

Neurana introduced the phase three RESUME-1 Study in December 2020. The double-blind, randomised, placebo controlled clinical trial was intended to evaluate the safety and efficiency of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions in 1,000 patients. The study randomised the patients equally to receive placebo or tolperisone 50mg, 100mg, or 200mg administered three times per day for 14 days.

Login
Username:

Password:


Related Headlines